Why the study?
Does CAP combination chemotherapy improve objective response compared to CMFVP in patients with untreated metastatic breast cancer?
Does CAP combination chemotherapy improve objective response compared to CMFVP in patients with untreated metastatic breast cancer?
CAP combination chemotherapy significantly improves objective response rates compared to CMFVP in untreated metastatic breast cancer, though with increased myelosuppression.
Answers are grounded in this paper and cite their sources.
CAP may be preferred for metastatic breast cancer; confirms randomized superiority in objective response.
The prospective controlled Phase III clinical trial tested the therapeutic value of the cis-platinum-adriamycin-cyclophosphamide combination (CAP), compared with the combination including cyclophosphamide, methotrexate, 5-fluorouracil, vincristine and prednisolone (CMFVP), in untreated metastatic breast cancer. One hundred and twenty-three patients (greater than 2 cycles) were evaluated: 61 on the CAP, and 62 on the CMFVP schedule. An objective response (CR + PR) to CAP combination chemotherapy was achieved in 72% of patients (43/61), with a high rate (36%) of complete remissions. In terms of metastatic site, the response rate appeared to be particularly high in soft tissue and visceral organ (lung, liver) metastases. In the CMFVP group, an objective response was noted in 26 of 62 patients (42%), with 16% complete remissions. The difference in overall therapeutic response - and in the complete remission rate as well - was statistically significant to the advantage of the CAP regimen (P less than 0.01). The duration of remissions was 6-28 + months (means = 14) for the CAP, and 4-15 + months (mean = 9) for the CMFVP schedule. Toxic side effects were more pronounced in the CAP group, particularly myelosuppression, with anemia prevailing. Side effects of CMFVP treatment were moderate. In 39 CMFVP previously treated cases, CAP was administered as second-line treatment, and an objective response was observed in 51% of cases (20/39). Results of this controlled trial showed the advantage of the CAP combination chemotherapy in the treatment of metastatic breast cancer.
No takes yet. Share an insight, caveat, or question.
Kolarić et al. (1985) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: